Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01753856
First received: December 18, 2012
Last updated: September 11, 2015
Last verified: September 2015

December 18, 2012
September 11, 2015
January 2013
June 2014   (final data collection date for primary outcome measure)
Change From Baseline to 3 Months in Mineralizing Surface (MS) /Bone Surface (BS) in the Cancellous Compartment (CC) of the Iliac Crest Bone Biopsies [ Time Frame: Baseline, 3 months post first dose of study drug ] [ Designated as safety issue: No ]
MS /BS is a measure of the proportion of BS on which new mineralized bone is deposited at the time of DEM or TET labeling, and calculated as the sum of the total extent of double label (DL) plus half the extent of single label (SL) divided by BS. At baseline (18 days prior to randomization / study drug administration), DEM was administered (3 days on, 12 days off, 3 days on). 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered (same dosing schedule as DEM). Both DEM and TET temporarily bind to new bone and fluoresce under UV light. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or no label (NL) suggested varying degrees of suppression of bone formation.
Change from Baseline to 3 Months in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01753856 on ClinicalTrials.gov Archive Site
  • Number of Samples With Single or Double Tetracycline Labels, SL and DL, or No Tetracycline Labels in the CC, Endocortical Compartment (EC), Intracortical Compartment (IC) and Periosteal Compartment (PC) of the Iliac Crest Bone Biopsies [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
  • Change From Baseline to 3 Months in MS/BS in the Endocortical Compartment (EC), Intracortical Compartment (IC), and Periosteal Compartment (PC) of the Iliac Crest Bone Biopsies [ Time Frame: Baseline, 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    MS /BS is a measure of the proportion of BS on which new mineralized bone is deposited at the time of DEM or TET labeling and is calculated as the sum of the total extent of DL plus half the extent of SL divided by BS. At baseline (18 days prior to randomization / study drug administration), DEM was administered (3 days on, 12 days off, 3 days on). 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered (same dosing schedule as DEM). Both DEM and TET temporarily bind to new bone and fluoresce under UV light. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggested varying degrees of suppression of bone formation.
  • MS/BS in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies 3 Months Post First Dose of Study Drug [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    MS /BS is a measure of the proportion of BS on which new mineralized bone is deposited at the time of DEM or TET labeling and is calculated as the sum of the total extent of DL plus half the extent of SL divided by BS. At baseline (18 days prior to randomization / study drug administration), DEM was administered (3 days on, 12 days off, 3 days on). 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered (same dosing schedule as DEM). Both DEM and TET temporarily bind to new bone and fluoresce under UV light. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggested varying degrees of suppression of bone formation.
  • Percentage of Bone With Remodeling-Based and Modeling-Based Formations in the CC, EC and PC of the Iliac Crest Bone Biopsies [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    In this study, post-treatment DLs in the CC, EC, and PC were classified as remodeling-based or modeling-based bone formations which was determined by whether the underlying reversal line was scalloped or smooth and by the collagen fiber orientation. Percentage = (remodeling-based formation units or modeling-based formation units/ total bone formation units) * 100.
  • Percentage of Mineralizing Surface With Remodeling-Based Formation and Modeling-Based Formation in the CC, EC and PC of the Iliac Crest Bone Biopsies [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]

    The percentage of mineralizing surface where post-treatment DLs in the CC, EC, and PC were classified as remodeling-based or modeling based bone formation based on collagen fiber orientation and whether the underlying reversal line was scalloped or smooth.

    Percentage = percentage remodeling- or modeling-based formation units * MS/BS

  • Percentage of Overfilled Remodeling Sites in the CC, EC and PC of the Iliac Crest Bone Biopsies [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    The percentage of overfilled remodeling sites in the CC, EC, and PC were defined as the percentage of observed remodeling units in which the second DL (TET) extended beyond the limits of the scalloped reversal line and into the adjacent, previously unresorbed surface of the bone. Percentage = (overfilled remodeling bone formation unit / total bone formation unit) * 100.
  • Change From Baseline to 3 Months in Label Length Within Each Basic Multicellular Unit (BMU) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies [ Time Frame: Baseline, 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    BMUs are local groups of osteoblasts and osteoclasts that act in concert to complete a single remodeling cycle. The label length is a measure of the extent of the mineralization front within each BMU in the CC, EC, IC and PC. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation, and a SL or NL suggested suppression of bone formation.
  • Change From Baseline to 3 Months in Mineral Apposition Rate (MAR) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies [ Time Frame: Baseline, 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    MAR is a measure of the linear rate of production of mineralized bone matrix by osteoblasts and is measured by the mean distance between 2 consecutive labels divided by the time interval. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation, and a SL or NL suggested suppression of bone formation. SL cases were imputed to a value of 0.3 micrometers per day (µm/day) or counted as missing. NL cases were reported as missing.
  • Change From Baseline to 3 Months in Bone Formation Rate/Bone Surface (BFR/BS ) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies [ Time Frame: Baseline, 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    BFR/BS is the volume of mineralized bone formed per unit surface of bone per unit of time [mm cubed per mm squared per year (mm³/mm²/year)]. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicates active bone formation, a SL or NL suggests suppression of bone formation. BFR = MAR * (MS/BS). SL cases were imputed to a value of 0.3 mcm/day or counted as missing. NL cases were assigned a value of zero.
  • Percentage of Single or Double Tetracycline Labels Per Bone Surface (sLS/BS or dLS/BS) in the CC, EC, IC and PC of the Iliac Crest Bone Biopsies [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggested suppression of bone formation. Percentage = (Single or double TET labels / BS) *100.
  • Percentage Change From Baseline to 1, 3, and 6 Months in Intact Parathyroid Hormone (PTH) [ Time Frame: Baseline, 1, 3, and 6 months post first dose of study drug ] [ Designated as safety issue: No ]
    PTH regulates calcium and phosphate metabolism in bone and kidney, and is typically measured in serum using the intact PTH assay. Percentage = (PTH value at specified time points - PTH value at baseline) / PTH value at baseline * 100.
  • Percentage Change From Baseline to 1, 3, and 6 Months in Serum Procollagen Type I N-terminal Propeptide (P1NP) [ Time Frame: Baseline, 1, 3, and 6 months post first dose of study drug ] [ Designated as safety issue: No ]
    P1NP is a marker of bone turnover and is a measure of bone formation. Percentage = (P1NP value at specified time points - P1NP value at baseline) / P1NP value at baseline * 100.
  • Percentage Change From Baseline to 1, 3, and 6 Months in Serum Osteocalcin [ Time Frame: Baseline, 1, 3, and 6 months post first dose of study drug ] [ Designated as safety issue: No ]
    Osteocalcin is a marker of bone turnover and a measure of osteoblast function. Percentage = (osteocalcin value at specified time points - osteocalcin value at baseline) / (osteocalcin value at baseline) * 100.
  • Percentage Change From Baseline to 1, 3, and 6 Months in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) [ Time Frame: Baseline, 1, 3, and 6 months post first dose of study drug ] [ Designated as safety issue: No ]
    CTX is a marker of bone turnover and is a measure of bone resorption. Percentage = (CTX value at specified time points - CTX value at baseline) / (CTX value at baseline) * 100.
  • Activation Frequency (Ac.f) in the CC, EC and IC of the Iliac Crest [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    Ac.f is the probability of new remodeling cycles initiated on the BS per year. Ac.f = (BFR/BS) / wall thickness. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggests suppression of bone formation. SL cases were imputed to a value of 0.3 µm/day or counted as missing. NL cases were assigned a value of zero.
  • Adjusted Apposition Rate (Aj.AR) in the CC, EC and IC of the Iliac Crest [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    Aj.AR is MAR averaged over the entire osteoid surface and in a steady state is an estimate of the mean rate of matrix apposition. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation and a SL or NL suggested suppression of bone formation. BFR = MAR * (MS/BS). SL cases were imputed to a value of 0.3 µm/day or counted as missing. NL cases were counted as missing.
  • Percentage of Osteoid Volume (OV)/Bone Volume (BV) in the CC of the Iliac Crest [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    OV is the percentage of a given volume of bone tissue that consists of new unmineralized bone matrix (osteoid). Percentage = (OV/BV) *100.
  • Percentage of Osteoid Surface (OS)/Bone Surface (BS) in the CC, EC and IC of the Iliac Crest [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    OS is the percentage of the entire trabecular BS that is covered by osteoid. Percentage = (OS / BS) *100.
  • Osteoid Thickness (O.Th) in the CC, EC and IC of the Iliac Crest [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    O.Th is a measure of the average thickness of osteoid seams.
  • Wall Thickness (W.Th) in the CC, EC and IC of the Iliac Crest [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    W.Th is the distance from the cement line to the marrow space of completed trabecular bone packets.
  • Percentage of Eroded Surface/Bone Surface (ES/BS) in the CC, EC and IC of the Iliac Crest [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
    ES/BS is the fraction of the entire trabecular surface occupied by resorption bays, including both those with and without osteoclasts. It is an indicator of bone resorption. Percentage = (ES/BS) *100.
  • Change from Baseline to 3 Months in Mineralizing Surface/Bone Surface (MS/BS) in the Endocortical Compartment, Intracortical Compartment, and Periosteal Compartment of Iliac Crest Bone Biopsies [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
  • Proportion of Bone with Remodeling-Based Formation and Modeling-Based Formation [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Proportion of Overfilled Remodeling Sites [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Change from Baseline to 3 Months in Label Length within each Basic Multicellular Unit (BMU) [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
  • Change from Baseline to 3 Months in Mineral Apposition Rate (MAR) [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
  • Change from Baseline to 3 Months in Bone Formation Rate (BFR) [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
  • Percent of Single or Double Tetracycline Labels per Bone Surface (sLS/BS), (dLS/BS) [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Change from Baseline to 3 Months in Intact Parathyroid Hormone (PTH) [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
  • Change from Baseline to 3 Months in Serum Procollagen Type I N-terminal Propeptide (P1NP) [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
  • Change from Baseline to 3 Months in Serum Osteocalcin [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
  • Change from Baseline to 3 Months in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX) [ Time Frame: Baseline, 3 Months ] [ Designated as safety issue: No ]
  • Activation Frequency (Ac.f ) [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Adjusted Apposition Rate (Aj.AR) [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Number of Samples with Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Percentage of Osteoid Volume (OV)/Bone Volume (BV) [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Percentage of Osteoid Surface (OS)/Bone Surface (BS) [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Osteoid Thickness (O.Th) [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Wall Thickness (W.Th) [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
  • Percentage of Eroded Surface/Bone Surface (ES/BS) [ Time Frame: 3 Months ] [ Designated as safety issue: No ]
Average Length of DLs in the CC, EC, IC and PC of the Iliac Crest [ Time Frame: 3 months post first dose of study drug ] [ Designated as safety issue: No ]
The length of TET DLs is a measure of the extent of bone formation in each compartment within individual remodeling units and is measured in mm. At baseline (18 days prior to randomization / study drug administration), DEM was administered. 22 days prior to the biopsy procedure (biopsy obtained 3 months post first dose of study drug), TET was administered. New bone in the biopsy was seen as the amount of bone between the 2 fluorescently DEM- or TET-labeled lines under a microscope. A DL indicated active bone formation.
Not Provided
 
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis
The purpose of this study is to determine how teriparatide or denosumab affects the bone of postmenopausal women with osteoporosis after 3 months of treatment, as determined by a bone biopsy sample taken from the iliac crest (upper part of the pelvis).
Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Osteoporosis
  • Drug: Teriparatide
    Administered SC
    Other Names:
    • LY333334
    • Forteo
    • Forsteo
  • Drug: Denosumab
    Administered SC
  • Drug: Demeclocycline
    Administered orally
  • Drug: Tetracycline
    Administered orally
  • Drug: Calcium Supplement
    Administered orally
  • Drug: Vitamin D
    Administered orally
  • Experimental: Teriparatide

    20 micrograms (µg) teriparatide administered subcutaneously (SC) once every day for 6 months.

    Demeclocycline (DEM): Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligrams (mg) DEM will be taken orally every 6 hours; Days 4 to15: DEM will not be administered.

    Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.

    Calcium: Approximately 1000 milligrams per day (mg/day) administered orally.

    Vitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally.

    Interventions:
    • Drug: Teriparatide
    • Drug: Demeclocycline
    • Drug: Tetracycline
    • Drug: Calcium Supplement
    • Drug: Vitamin D
  • Active Comparator: Denosumab

    60 mg denosumab administered SC once in 6 months.

    DEM: Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 mg DEM will be taken orally every 6 hours; Days 4 to 15: DEM will not be administered.

    TET: Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.

    Calcium: Approximately 1000 mg/day administered orally.

    Vitamin D: Approximately 800 to 1200 IU/day administered orally.

    Interventions:
    • Drug: Denosumab
    • Drug: Demeclocycline
    • Drug: Tetracycline
    • Drug: Calcium Supplement
    • Drug: Vitamin D
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
69
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ambulatory, postmenopausal women (no vaginal bleeding for at least 2 years prior to screening) with osteoporosis
  • Bone mineral density (BMD) T-score of at least -2.5 at femoral neck (FN), total hip (TH), or lumbar spine (LS) (Lumbar vertebrae L1-L4, with at least 2 evaluable vertebrae), with or without atraumatic fracture after menopause, OR
  • BMD T-score of at least -1.5 at FN, TH, or LS (L1-L4, with at least 2 evaluable vertebrae), and 1 or more atraumatic fractures after menopause (vertebral or nonvertebral). Nonvertebral fracture sites allowed are wrist, hip, pelvis, rib, humerus, clavicle, leg (femur, tibia, and fibula, excluding ankle)
  • Laboratory values for serum calcium, parathyroid hormone (PTH), and alkaline phosphatase must be within the normal reference range

Exclusion Criteria:

  • Has an increased risk of osteosarcoma (bone tumor); this includes Paget's disease of bone, a previous bone tumor, or radiation involving the skeleton
  • Has an allergy or intolerance to teriparatide or denosumab and/or is a poor candidate for teriparatide or denosumab treatment (investigator should refer to local product prescribing information)
  • Has a history of exposure to DEM or TET therapy in the 12 months prior to screening or a known allergy to DEM or TET
  • Has a condition that could put the participant at additional risk of an adverse event (AE) due to the bone biopsy procedure (for example, bleeding disorder)
  • Has undergone 2 previous iliac crest bone biopsies (1 in each iliac crest)
  • Has a 25-hydroxyvitamin D concentration of <10 nanograms per milliliter (ng/mL)
  • Has currently active or suspected (within 1 year prior to enrollment) diseases that affect bone metabolism, other than osteoporosis (such as renal osteodystrophy, hyperthyroidism, osteomalacia, or hyperparathyroidism)
  • Has a history of certain cancers within 5 years prior to trial entry
  • Current or recent (within 1 year prior to enrollment) celiac disease, inflammatory bowel disease, gastric bypass, or other malabsorption syndrome
  • Has significantly impaired hepatic or renal function
  • Has had treatment with systemic glucocorticoids in doses ≥5 mg/day prednisone/day or equivalent in the 6 calendar months prior to screening
  • Has taken any intravenous osteoporosis medication
  • Has had prior treatment with other bisphosphonates and not been off of them for a specific period of time before trial entry
  • Has participated in any other clinical trial studying teriparatide, PTH, PTH analog, or denosumab, or prior or current treatment with teriparatide, PTH, PTH analog, or denosumab
Female
55 Years to 89 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT01753856
14592, B3D-US-GHDV
No
Not Provided
Not Provided
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP